Two Sigma Investments LP Has $1.93 Million Position in Haleon plc (NYSE:HLN)

Two Sigma Investments LP lowered its holdings in Haleon plc (NYSE:HLN - Free Report) by 72.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 202,492 shares of the company's stock after selling 526,712 shares during the quarter. Two Sigma Investments LP's holdings in Haleon were worth $1,932,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after acquiring an additional 475,934 shares during the period. Atria Wealth Solutions Inc. boosted its position in Haleon by 6.1% in the fourth quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company's stock valued at $457,000 after buying an additional 2,758 shares in the last quarter. Savant Capital LLC boosted its position in Haleon by 99.2% in the fourth quarter. Savant Capital LLC now owns 26,393 shares of the company's stock valued at $252,000 after buying an additional 13,142 shares in the last quarter. American Century Companies Inc. boosted its position in Haleon by 6.1% in the fourth quarter. American Century Companies Inc. now owns 719,890 shares of the company's stock valued at $6,868,000 after buying an additional 41,189 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in Haleon in the fourth quarter valued at about $761,000. Institutional investors own 6.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HLN. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Haleon has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Price Performance

Shares of HLN stock traded up $0.18 during trading hours on Thursday, reaching $11.11. 13,674,281 shares of the company were exchanged, compared to its average volume of 8,687,486. Haleon plc has a fifty-two week low of $8.25 and a fifty-two week high of $11.42. The stock's fifty day moving average is $10.48 and its two-hundred day moving average is $10.02. The company has a market cap of $50.00 billion, a price-to-earnings ratio of 32.66, a P/E/G ratio of 2.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.